The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients

Malgorzata Kloc; Rafik M. Ghobrial

doi:10.1016/j.msard.2020.102437

The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients

Malgorzata Kloc, Rafik M. Ghobrial

Research output: Contribution to journal › Comment/debate › peer-review

16 Scopus citations

Abstract

We encourage studies on the effectiveness of multiple sclerosis drugs for the treatment of ARDS in COVID-19 infection. These drugs, through the inhibition of the RhoA/actin-dependent expression of virus receptors in the macrophages and macrophage recruitment to the lungs, have the potential to inhibit cytokine storm of lung macrophages, reduce or eliminate ARDS and improve the outcome of COVID-19 infection.

Original language	English (US)
Article number	102437
Journal	Multiple Sclerosis and Related Disorders
Volume	45
DOIs	https://doi.org/10.1016/j.msard.2020.102437
State	Published - Oct 2020

Keywords

Azetidines/therapeutic use
Benzyl Compounds/therapeutic use
Betacoronavirus/drug effects
Coronavirus Infections/complications
Enzyme Inhibitors/therapeutic use
Fingolimod Hydrochloride/therapeutic use
Humans
Multiple Sclerosis/drug therapy
Pandemics
Pneumonia, Viral/complications
Respiratory Distress Syndrome, Adult/drug therapy
rhoA GTP-Binding Protein/antagonists & inhibitors

ASJC Scopus subject areas

Clinical Neurology
Neurology

Divisions

Abdominal Transplant

Access to Document

10.1016/j.msard.2020.102437

Cite this

@article{34bb4dda2c644e74be48381750c98d4f,

title = "The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients",

abstract = "We encourage studies on the effectiveness of multiple sclerosis drugs for the treatment of ARDS in COVID-19 infection. These drugs, through the inhibition of the RhoA/actin-dependent expression of virus receptors in the macrophages and macrophage recruitment to the lungs, have the potential to inhibit cytokine storm of lung macrophages, reduce or eliminate ARDS and improve the outcome of COVID-19 infection.",

keywords = "Azetidines/therapeutic use, Benzyl Compounds/therapeutic use, Betacoronavirus/drug effects, Coronavirus Infections/complications, Enzyme Inhibitors/therapeutic use, Fingolimod Hydrochloride/therapeutic use, Humans, Multiple Sclerosis/drug therapy, Pandemics, Pneumonia, Viral/complications, Respiratory Distress Syndrome, Adult/drug therapy, rhoA GTP-Binding Protein/antagonists \& inhibitors",

author = "Malgorzata Kloc and Ghobrial, \{Rafik M.\}",

year = "2020",

month = oct,

doi = "10.1016/j.msard.2020.102437",

language = "English (US)",

volume = "45",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients

AU - Kloc, Malgorzata

AU - Ghobrial, Rafik M.

PY - 2020/10

Y1 - 2020/10

N2 - We encourage studies on the effectiveness of multiple sclerosis drugs for the treatment of ARDS in COVID-19 infection. These drugs, through the inhibition of the RhoA/actin-dependent expression of virus receptors in the macrophages and macrophage recruitment to the lungs, have the potential to inhibit cytokine storm of lung macrophages, reduce or eliminate ARDS and improve the outcome of COVID-19 infection.

AB - We encourage studies on the effectiveness of multiple sclerosis drugs for the treatment of ARDS in COVID-19 infection. These drugs, through the inhibition of the RhoA/actin-dependent expression of virus receptors in the macrophages and macrophage recruitment to the lungs, have the potential to inhibit cytokine storm of lung macrophages, reduce or eliminate ARDS and improve the outcome of COVID-19 infection.

KW - Azetidines/therapeutic use

KW - Benzyl Compounds/therapeutic use

KW - Betacoronavirus/drug effects

KW - Coronavirus Infections/complications

KW - Enzyme Inhibitors/therapeutic use

KW - Fingolimod Hydrochloride/therapeutic use

KW - Humans

KW - Multiple Sclerosis/drug therapy

KW - Pandemics

KW - Pneumonia, Viral/complications

KW - Respiratory Distress Syndrome, Adult/drug therapy

KW - rhoA GTP-Binding Protein/antagonists & inhibitors

UR - https://www.scopus.com/pages/publications/85089006730

UR - https://www.scopus.com/inward/citedby.url?scp=85089006730&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2020.102437

DO - 10.1016/j.msard.2020.102437

M3 - Comment/debate

C2 - 32763844

AN - SCOPUS:85089006730

SN - 2211-0348

VL - 45

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

M1 - 102437

ER -

The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients

Abstract

Keywords

ASJC Scopus subject areas

Divisions

Access to Document

Other files and links

Fingerprint

Cite this